Biodexa Pharmaceuticals plc American Depositary Shs (BDRX)
Stock · NASDAQ · Health Care
$0.4483as of 10/16/2026
Price chart
Active signals
BDRX Signal Track Record
How signals performed across all stocks →What BDRX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakdown | 27 | -30.3% | 22% | August 20, 2026 |
| Volume Spike | 15 | -29.6% | 0% | September 15, 2026 |
| Bollinger Band Breakout | 13 | -34.8% | 8% | May 5, 2026 |
| Any 20-session window (baseline) | -20.0% | 19% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About BDRX
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. T…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 11
- Website
- www.biodexapharma.com/
Fundamentals
- 1-day range
- $0.4401$0.47
- Market cap
- $1.10M
- P/E (trailing)
- —
- P/E (forward)
- Infinity
- EPS (trailing)
- $-0.00
- Dividend yield
- —
- Beta
- 1.28
- Avg. volume
- 4.94M
- Dividend pay date
- March 3, 2020
Forecasts
1 analyst ratings
Biodexa Pharmaceuticals plc American Depositary Shs Competitors
Chosen by industry and closest market cap.
- BDRXBiodexa Pharmaceuticals plc American Depositary Shs$0.456▲ 5.80%Market cap $1.10MP/E —$0.3371$44.7
- BIVIWBioVie Inc. Warrant$0.2301▼ 7.96%Market cap $1.06MP/E —$0.13$0.79
- MTNBMatinas Biopharma Holdings Inc. Common Stock$2.37▼ 2.07%Market cap $1.72MP/E —$2.26$28.95
- CMNDClearmind Medicine Inc. Common Shares$6.26▼ 2.49%Market cap $1.78MP/E —$5.25$3,840
- BFRIWBiofrontera Inc. Warrants$0.0052▼ 7.14%Market cap $357.2KP/E —$0.0052$0.1484
- BFRGWBullfrog AI Holdings Inc. Warrants$0.13▲ 25.85%Market cap $2.04MP/E —$0.0751$0.6488
- SXTCChina SXT Pharmaceuticals Inc. Class A Ordinary Shares$0.065▼ 5.80%Market cap $2.06MP/E —$0.0619$83,758
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| BDRX Biodexa Pharmaceuticals plc American Depositary Shs | $1.10M | — | $0.456 | ▲ 5.80% | $0.3371$44.7 |
| BIVIW BioVie Inc. Warrant | $1.06M | — | $0.2301 | ▼ 7.96% | $0.13$0.79 |
| MTNB Matinas Biopharma Holdings Inc. Common Stock | $1.72M | — | $2.37 | ▼ 2.07% | $2.26$28.95 |
| CMND Clearmind Medicine Inc. Common Shares | $1.78M | — | $6.26 | ▼ 2.49% | $5.25$3,840 |
| BFRIW Biofrontera Inc. Warrants | $357.2K | — | $0.0052 | ▼ 7.14% | $0.0052$0.1484 |
| BFRGW Bullfrog AI Holdings Inc. Warrants | $2.04M | — | $0.13 | ▲ 25.85% | $0.0751$0.6488 |
| SXTC China SXT Pharmaceuticals Inc. Class A Ordinary Shares | $2.06M | — | $0.065 | ▼ 5.80% | $0.0619$83,758 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Biodexa Pharmaceuticals Enrolls 100 Patients In Its Registrational Phase 3 Serenta Trial Of eRapa In Familial Adenomatous Polyposis; Trial Is Recruiting At 29 Clinical Sites In U.S., Canada And Europe And Is Expected To Be Initiated Shortlybenzinga · 10/13/2026
- Here are the top movers in Thursday's session.ChartMill · 9/17/2026
- 12 Health Care Stocks Moving In Thursday's Intraday SessionBenzinga · 9/17/2026
- 12 Health Care Stocks Moving In Thursday's Pre-Market SessionBenzinga · 9/17/2026
- What's going on in today's sessionChartMill · 9/16/2026
- Keep an eye on the top gainers and losers in Wednesday's session.ChartMill · 9/16/2026
- 12 Health Care Stocks Moving In Wednesday's Intraday SessionBenzinga · 9/16/2026
- Tuesday's session: most active stocksChartMill · 9/15/2026
- Unusual volume stocks are being observed in Tuesday's session.ChartMill · 9/15/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 151
- Total value held
- $93
- Institutional holders
- 1
- Unknown151
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
BDRX announces 1-for-8 reverse ADS split effective Oct 26
Biodexa Pharmaceuticals announced a 1‑for‑8 reverse ADS split that will take effect on October 26. The split will combine eight existing ADS into one, raising the share price proportionally while reducing the total number of shares. The move comes as the stock is trading near its $0.62 support level and shows a low RSI, indicating limited price momentum. Investors may watch how the split influences market perception.
BDRX announces 1-for-8 reverse ADS split effective Oct 26. Biodexa Pharmaceuticals announced a 1‑for‑8 reverse ADS split that will take effect on October 26. The split will combine eight existing ADS into one, raising the share price proportionally while reducing the total number of shares. The move comes as the stock is trading near its $0.62 support level and shows a low RSI, indicating limited price momentum. Investors may watch how the split influences market perception.